


Oral contraceptives lower ovarian cancer risk in BRCA carriers

July 7 2021



(HealthDay)—Oral contraceptive use is associated with a reduced risk

for ovarian cancer for *BRCA* mutation carriers, according to a study published in the July issue of the *American Journal of Obstetrics & Gynecology*.

Lieske H. Schrijver, from the Netherlands Cancer Institute in Amsterdam, and colleagues examined the correlation of various characteristics of oral contraceptive use and the risk for ovarian cancer among 3,989 *BRCA1* and 2,445 *BRCA2* mutation carriers.

The researchers found that mutation carriers who were diagnosed with ovarian cancer had less frequent use of oral contraceptives (ever use: 58.6 percent for *BRCA1* and 53.5 percent for *BRCA2*) compared with unaffected carriers (88.9 and 80.7 percent, respectively). *BRCA1* and *BRCA2* carriers who developed ovarian cancer had a median duration of oral contraceptive use of seven years compared with nine and eight years, respectively, in unaffected carriers. In univariate analyses, a longer duration of oral contraceptive use and more recent use were both associated with a reduction in the risk for ovarian cancer for *BRCA1* carriers. In multivariate analyses, duration of oral contraceptive use was the prominent protective factor (hazard ratios, 0.67 and 0.37 for five to nine years and ≥ 10 years, respectively, compared with

Citation: Oral contraceptives lower ovarian cancer risk in BRCA carriers (2021, July 7) retrieved 3 February 2024 from <https://medicalxpress.com/news/2021-07-oral-contraceptives-ovarian-cancer-brca.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.